Cryoport Reports Third Quarter 2026 Financial Results
<p>Third quarter revenue grew 14% year-over-year to $50.2 million Commercial Cell and Gene Therapy revenue increased 20% year-over-year Supporting a record 788 global clinical trials and 23 commercially approved cell and gene therapies as of September 30, 2026 Raises full-year 2026 revenue...</p>
Read original article ↗
Related Articles
Palantir signs partnership with Korean footwear manufacturer
Few people who lace up a pair of Nike sneakers have heard of Changshin, but there is a good chance the Busan-based compa
Lam Research appoints Kim Tae-won as new Korea head
Lam Research said Friday it has appointed Kim Tae-won as the new head of its Korean operations, succeeding Park Joon-hon
Hua Hong Grace eyes silicon photonics expansion as AI chip shortages lift pricing power
China's second-largest contract chipmaker, Hua Hong Grace Semiconductor, is expanding into silicon photonics and power m